U.S. Markets closed

Endonovo Therapeutics Announces Complimentary New Product

LOS ANGELES, CA, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced the expansion of their suite of complimentary products with the ORTHOHALO™.

ORTHOHALO™ is an easy-to-use, non-invasive device delivering targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation. There are no known side effects and no potential for overdose or dependency.

Alan Collier, CEO of Endonovo Therapeutics, stated, “My team and I have been working diligently identifying opportunities to leverage our technologies while addressing the needs of current and potential customers in our ongoing efforts to provide patients Opioid alternatives. ORTHOHALO™ allows us to strengthen our industry reach and further revenue generation. In addition, this allows us the opportunity to have broader discussions during each customer visit, providing more comprehensive solutions and further establishing our credibility and ability to address each unique market.”

About ORTHOHALO™

ORTHOHALO™ is a new product line designed to provide personalized treatments for orthopedic, sports, and on the job injuries. ORTHOHALO™ aims to accomplish this by providing each patient a customized application that can be used in conjunction with a wide range of bracing, splint, and other products. ORTHOHALO™ is the only PEMF device that can be used to provide around-the-clock pain management and edema control for orthopedic patients.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact: 

Endonovo Therapeutics, Inc. 
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com 
www.endonovo.com